• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Novelos Therapeutics to Present at MUSC Conference on Cancer Drug Discovery and Development

Posted on: Thursday, 15 March 2007, 09:01 CDT

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Christopher J. Pazoles, Ph.D., Vice President of R&D of Novelos, will present at the 2007 Hollings Cancer Center Spring Symposium entitled "Cancer Drug Discovery and Development: Bridging Academic and Industry Partnerships" on March 23-24, 2007 in Kiawah Island, SC. The symposium, organized by the Medical University of South Carolina (MUSC), will focus on the science, clinical testing and business aspects underlying the development of novel cancer therapeutics.

Dr. Pazoles will present a talk entitled "NOV-002: Oxidized Glutathione as a Novel Platform for Cancer Therapeutics" that will highlight clinical and non-clinical findings with Novelos' lead compound, currently in Phase 3 and Phase 2 clinical development for treatment of various solid tumor cancers. He will emphasize modulation of redox-sensitive cell signaling pathways by NOV-002 (a proprietary formulation of oxidized glutathione) together with its effects on the glutathione pathway.

"This conference offers a unique opportunity to discuss Novelos' technology with prominent leaders at the industry/academia interface," said Dr. Pazoles. "Research collaborations with academic institutions of excellence such as Medical University of South Carolina and others are an integral part of our research and development program."

Information about the conference is available at http://hcc.musc.edu/research/spring/

About Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and an immunomodulator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer, and is in addition being developed for acute radiation injury. NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed. For additional information about Novelos please visit www.novelos.com

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

Source: Business Wire

More News in this Category